EE200300551A - Adenosiini ja selle analoogide kasutamine ravimi valmistamiseks insuliiniresistentsuse sündroomi jadiabeedi raviks - Google Patents

Adenosiini ja selle analoogide kasutamine ravimi valmistamiseks insuliiniresistentsuse sündroomi jadiabeedi raviks

Info

Publication number
EE200300551A
EE200300551A EEP200300551A EEP200300551A EE200300551A EE 200300551 A EE200300551 A EE 200300551A EE P200300551 A EEP200300551 A EE P200300551A EE P200300551 A EEP200300551 A EE P200300551A EE 200300551 A EE200300551 A EE 200300551A
Authority
EE
Estonia
Prior art keywords
adenosine
analogues
medicament
manufacture
treatment
Prior art date
Application number
EEP200300551A
Other languages
English (en)
Estonian (et)
Inventor
Herling Andreas
J�hne Gerhard
P. Maguire Martin
P. Spada Alfred
R. Myers Michael
Mi Choi-Sledeski Yong
W. Pauls Heinz
R. Ewing William
Original Assignee
Aventis Pharma Deutschland Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Deutschland Gmbh filed Critical Aventis Pharma Deutschland Gmbh
Publication of EE200300551A publication Critical patent/EE200300551A/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16Purine radicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52Purines, e.g. adenine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
EEP200300551A 2001-05-14 2002-05-14 Adenosiini ja selle analoogide kasutamine ravimi valmistamiseks insuliiniresistentsuse sündroomi jadiabeedi raviks EE200300551A (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01111651A EP1258247A1 (en) 2001-05-14 2001-05-14 Adenosine analogues for the treatment of insulin resistance syndrome and diabetes
PCT/EP2002/005301 WO2002092093A1 (en) 2001-05-14 2002-05-14 Adenosine analogues for the treatment of the insulin resistance syndrome and diabetes

Publications (1)

Publication Number Publication Date
EE200300551A true EE200300551A (et) 2004-02-16

Family

ID=8177414

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200300551A EE200300551A (et) 2001-05-14 2002-05-14 Adenosiini ja selle analoogide kasutamine ravimi valmistamiseks insuliiniresistentsuse sündroomi jadiabeedi raviks

Country Status (23)

Country Link
US (1) US20030176390A1 (cs)
EP (2) EP1258247A1 (cs)
JP (1) JP2004533448A (cs)
KR (1) KR20040002962A (cs)
CN (1) CN1518450A (cs)
BG (1) BG108356A (cs)
BR (1) BR0209650A (cs)
CA (1) CA2447408A1 (cs)
CO (1) CO5540288A2 (cs)
CZ (1) CZ20033079A3 (cs)
EA (1) EA007253B1 (cs)
EE (1) EE200300551A (cs)
HR (1) HRP20030928A2 (cs)
HU (1) HUP0400464A3 (cs)
IL (1) IL158794A0 (cs)
MX (1) MXPA03010336A (cs)
NO (1) NO20035056D0 (cs)
NZ (1) NZ529390A (cs)
PL (1) PL364573A1 (cs)
SK (1) SK14052003A3 (cs)
WO (1) WO2002092093A1 (cs)
YU (1) YU90203A (cs)
ZA (1) ZA200308777B (cs)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GT200500281A (es) * 2004-10-22 2006-04-24 Novartis Ag Compuestos organicos.
GB0500785D0 (en) * 2005-01-14 2005-02-23 Novartis Ag Organic compounds
GB0607948D0 (en) * 2006-04-21 2006-05-31 Novartis Ag Organic compounds
MY146645A (en) 2006-04-21 2012-09-14 Novartis Ag Purine derivatives for use as adenosin a2a receptor agonists
GB0607953D0 (en) * 2006-04-21 2006-05-31 Novartis Ag Organic compounds
GB0607944D0 (en) * 2006-04-21 2006-05-31 Novartis Ag Organic compounds
GB0607950D0 (en) * 2006-04-21 2006-05-31 Novartis Ag Organic compounds
EP1889846A1 (en) 2006-07-13 2008-02-20 Novartis AG Purine derivatives as A2a agonists
EP1903044A1 (en) * 2006-09-14 2008-03-26 Novartis AG Adenosine Derivatives as A2A Receptor Agonists
MX2009004991A (es) * 2006-11-10 2009-05-20 Novartis Ag Derivados de monoacetato de ciclopenteno-diol.
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
WO2009131196A1 (ja) * 2008-04-24 2009-10-29 武田薬品工業株式会社 置換ピロリジン誘導体およびその用途
EP2582709B1 (de) 2010-06-18 2018-01-24 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
CN119798352B (zh) * 2024-01-15 2025-11-11 中国医学科学院药物研究所 化合物yzg-331的晶型及其制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8729994D0 (en) * 1987-12-23 1988-02-03 Glaxo Group Ltd Chemical compounds
US5055569A (en) * 1989-10-19 1991-10-08 G. D. Searle & Co. N-(6)-substituted adenosine compounds
HUT61567A (en) * 1990-12-07 1993-01-28 Sandoz Ag Process for producing new pharmaceutical compositions comprising 2'-o-alkyladenosine derivatives and for producing 6-cyclohexyl-2'-o-methyladenosinehydrate
UA51716C2 (uk) * 1996-07-08 2002-12-16 Авентіс Фармасьютікалз Продактс Інк. Сполуки, що мають гіпотензивну, кардіопротекторну, анти-ішемічну та антиліполітичну властивості, фармацевтична композиція та способи лікування
US6376472B1 (en) * 1996-07-08 2002-04-23 Aventis Pharmaceuticals, Inc. Compounds having antihypertensive, cardioprotective, anti-ischemic and antilipolytic properties
GB9723590D0 (en) * 1997-11-08 1998-01-07 Glaxo Group Ltd Chemical compounds
US6258793B1 (en) * 1999-12-03 2001-07-10 Cv Therapeutics, Inc. N6 heterocyclic 5′ modified adenosine derivatives

Also Published As

Publication number Publication date
IL158794A0 (en) 2004-05-12
MXPA03010336A (es) 2004-03-16
CZ20033079A3 (cs) 2004-08-18
EA007253B1 (ru) 2006-08-25
BG108356A (bg) 2004-12-30
CO5540288A2 (es) 2005-07-29
ZA200308777B (en) 2006-04-26
US20030176390A1 (en) 2003-09-18
EA200301231A1 (ru) 2004-04-29
WO2002092093A1 (en) 2002-11-21
KR20040002962A (ko) 2004-01-07
EP1404338A1 (en) 2004-04-07
NZ529390A (en) 2006-06-30
HUP0400464A3 (en) 2007-03-28
SK14052003A3 (sk) 2004-07-07
HUP0400464A2 (hu) 2004-07-28
PL364573A1 (en) 2004-12-13
EP1258247A1 (en) 2002-11-20
CA2447408A1 (en) 2002-11-21
BR0209650A (pt) 2004-07-13
JP2004533448A (ja) 2004-11-04
CN1518450A (zh) 2004-08-04
HRP20030928A2 (en) 2005-10-31
YU90203A (sh) 2006-08-17
NO20035056D0 (no) 2003-11-13

Similar Documents

Publication Publication Date Title
EE200300551A (et) Adenosiini ja selle analoogide kasutamine ravimi valmistamiseks insuliiniresistentsuse sündroomi jadiabeedi raviks
IL161155A0 (en) Treatment of insulin resistance syndrome and type 2 diabetes with pde9 inhibitors
NO2024004I1 (no) insulin degludec
EE200400029A (et) Kristalliline antikolinergikum, meetod selle valmistamiseks ja selle kasutamine ravimi valmistamiseks
EP1395294A4 (en) PULMONARY ADMINISTRATION OF CHEMICALLY MODIFIED INSULIN
IL176259A (en) Use of cystamine in combination with metformin to prepare a cure for diabetes or related complications
DE60044041D1 (de) Exendine zur Glucagon Suppression
AU2003275301A8 (en) Drug delivery device having coated microprojections incorporating vasoconstrictors
AU2001279593A1 (en) A substance for use in a dietary supplement or for the preparation of a medicament for the treatment of non-insulin dependent diabetes mellitus, hypertension and/or the metabolic syndrome
IL174033A0 (en) Multi-system therapy for diabetes, the metabolic syndrome and obesity comprising a hypoglycemic agent
WO2004050115A3 (en) Combination treatment using exendin-4 and thiazolidinediones
IS7800A (is) Aðferð við meðhöndlun á insúlínviðnámi, sykursýkitilkominni í fullorðnum og efnaskiptaheilkenni X
DE60103512D1 (de) Pharmazeutische zusammensetzung enthaltend pemetrexed zusammen mit monothioglycerol, l-cystein oder thioglykolsäure
AU2003252182A8 (en) Therapeutic treatment for the metabolic syndrome and type 2 diabetes
EE200300398A (et) Isoksasoliini derivaat, selle saamine ja kasutamine depresioonivastase ravimi valmistamiseks ning seda sisaldav ravimkompositsioon
ZA200405342B (en) The use of melagatran for the manufacture of a medicament for the treatment of type i diabetes mellitus
ZA200708641B (en) Use of nefopam and analogues thereof for the treatment of a syndrome characterised by chronic pain and fatigue
GB0606001D0 (en) Combination Of Cicletanine And An Oral Antidiabetic And/Or Blood Lipid-Lowering Agent For Treating Diabetes And Metabolic Syndrome
EE200200480A (et) Memnopeptiidühend, selle valmistamine ja raviotstarbeline kasutamine ning seda sisaldav farmatseutiline kompositsioon
CL2004000399A1 (es) Compuestos derivados de 1,3-oxazol sustituidos de formula i; composicion farmaceutica; procedimiento de preparacion de la composicion farmaceutica; y su uso en el tratamiento de la resistencia a la insulina, dislipidemia diabetes mellitus.
GB0117134D0 (en) Treatment of the insulin resistance syndrome
GB0106465D0 (en) Treatment of the insulin resistance syndrome
BR0309375A (pt) Tratamento de sìndrome metabólica
EE200300563A (et) Bensüülaminopürimidiiniühendid, nende kasutamine ja ravim
GB0030649D0 (en) Treatment of the insulin resistance syndrome